London-based Thriva raises €4.4 million Series A extension for its home blood tests

British startup Thriva, the ‘proactive health’ startup, has secured a €4.4 million extension to its Series A funding round from Target Global’s new Early Stage Fund II, which will top up the €6.7 million Series A raised in 2019. 

Thriva, founded in 2015, is rapidly becoming the go-to brand in the ‘proactive health’ category, an increasingly mainstream movement in which people are taking control of their own health. Thanks to Thriva, customers can understand, keep track of and improve what’s happening inside their bodies. Its at-home testing kits are processed by UKAS accredited laboratories and can analyse anything from indicators of heart disease and diabetes, to vitamins and minerals and hormone function. 

The startup has recently launched new personalised health plans and high quality supplements, which it delivers via partnerships with hospitals and other healthcare providers that wish to provide at-home testing to their patients and clients. So far the startup has processed over 115,000 test at-home blood tests in the last 4 years, with 76% of Thriva users achieving an improvement in at least one of their biomarkers between tests.

The company, which was founded by Hamish Grierson, Eliot Brooks and Tom Livesey, continues to grow 100% year-on-year and has expanded its team significantly to 50 team members in the company’s London Headquarters.

The investment, which takes Thriva’s total funding to around €12 million, will support the startup as it expands its at-home health service designed to help people stay on the front foot with their health and to continue putting better health in their hands.

Hamish Grierson, co-founder and CEO of Thriva said: “As the world faces unprecedented challenges posed by the coronavirus crisis, we have all been forced to view our health, and our mortality, in a new light. We believe that now and in the near future, people will be taking a more proactive approach to their own health and wellbeing. Whilst we cannot protect ourselves entirely from the tragic effects of a global pandemic like COVID-19, this period may inspire people to invest in their general health for the long-term.”

Dr Ricardo Schäfer, Partner at Target Global said: “When we first met the team behind Thriva, we were immediately hooked by their mission to allow people to take health into their own hands. Thriva has all the right ingredients to become one of those transforming category leaders we are seeking to back at Target Global. We are witnessing a shift in consumer behavior towards an increasingly proactive approach to health: people want to know what’s going on inside their bodies. Covid-19 is further accelerating this trend, which requires remote blood testing. Thriva is playing an essential role in providing a solution for increasing the test volume. We are excited to partner with Hamish, Eliot, and Tom at this pivotal point in time for the company.”

EU-Startups

Thriva raises £4M from Target in an era when at-home blood testing is more crucial than ever

Thriva emerged in 2016 as an at-home blood-testing startup allowing people to check, for instance, cholesterol levels. In the era of a pandemic, however, at-home blood testing is about to become quite a big deal, alongside the general trend toward people proactively taking control of their health.

It has secured a £4 million extension to its Series A funding round from Berlin-based VC Target Global . The investment takes Thriva’s total funding to £11 million. The investment comes from Target Global’s new Early Stage Fund II and will top up the £6 million Series A raised in 2019. Existing investors include Guinness Asset Management and Pembroke VCT.

Thriva has processed more than 115,000 at-home blood tests since 2016. Interestingly, these customers actually use the information to improve their health, with 76% of Thriva users achieving an improvement in at least one of their biomarkers between tests.

The startup has also launched personalized health plans and high-quality supplements, scaling up its partnerships with hospitals and other healthcare providers.

Founded by Hamish Grierson, Eliot Brooks and Tom Livesey, it claims to be growing 100% year-on-year and has expanded its team to 50 members in the company’s London headquarters.

In a statement Grierson said: “As the world faces unprecedented challenges posed by the coronavirus crisis, we have all been forced to view our health, and our mortality, in a new light.”

Speaking to TechCrunch he added: “While there are other at-home testing companies, we don’t see them as directly competitive. Thriva isn’t a testing company. Our at-home blood tests are an important data point but they’re just the beginning of the long-term relationships we’re creating with our customers. To deliver on our mission of putting better health in your hands, we not only help people to keep track of what’s really happening inside their bodies, we actually help them to make positive changes that they can see the effects of over time.”

Dr. Ricardo Schäfer, partner at Target Global said: “When we first met the team behind Thriva, we were immediately hooked by their mission to allow people to take health into their own hands.”

Startups – TechCrunch

[DarioHealth in Yahoo Finance] DarioHealth Self-test Blood Glucose Meters Can Now Be Utilized Within Hospitals During the COVID-19 Pandemic Per Recently Issued Emergency FDA Guidelines

NEW YORK, May 6, 2020 /PRNewswire/ — DarioHealth Corp. (Nasdaq: DRIO), a global digital therapeutics (DTx) innovator, announced today that in an effort to reduce contact between healthcare providers and patients in hospital settings, limit COVID-19 exposure, and preserve personal protective equipment (PPE), the U.S. Food and Drug

Read more here.

The post [DarioHealth in Yahoo Finance] DarioHealth Self-test Blood Glucose Meters Can Now Be Utilized Within Hospitals During the COVID-19 Pandemic Per Recently Issued Emergency FDA Guidelines appeared first on OurCrowd.

OurCrowd

[DarioHealth in FDA Health News] DARIOHEALTH: Self-test Blood Glucose Meters Can Now Be Utilized Within Hospitals During the COVID-19 Pandemic Per Recently Issued Emergency FDA Guidelines

DarioHealth Corp. (Nasdaq: DRIO), a global digital therapeutics (DTx) innovator, announced today that in an effort to reduce contact between healthcare providers and patients in hospital settings, limit COVID-19 exposure, and preserve personal protective equipment (PPE), the U.S. Food and Drug Administration (FDA) has recognized that home-use blood glucose meters including Dario’s smartphone-connected metering device may be used by patients with diabetes who are hospitalized due to COVID-19 to check their own blood glucose levels and provide the readings to the health care personnel caring for them.

Read more here.

The post [DarioHealth in FDA Health News] DARIOHEALTH: Self-test Blood Glucose Meters Can Now Be Utilized Within Hospitals During the COVID-19 Pandemic Per Recently Issued Emergency FDA Guidelines appeared first on OurCrowd.

OurCrowd

[Scopio in Yahoo Finance] Scopio Labs Receives CE Mark for X100 Microscope and Decision Support System With Full Field Peripheral Blood Smear (PBS) Application

TEL AVIV, Israel, April 13, 2020 /PRNewswire/ — Scopio Labs, a company advancing digital microscopy, today announced it has received CE mark certification for its X100 Full Field Peripheral Blood Smear (Full Field PBS) all-digital morphology analysis platform.

Read more here.

The post [Scopio in Yahoo Finance] Scopio Labs Receives CE Mark for X100 Microscope and Decision Support System With Full Field Peripheral Blood Smear (PBS) Application appeared first on OurCrowd.

OurCrowd

[Sight Diagnostics in Forbes] Complete Blood Count Testers Say Their Products Can Monitor COVID-19 Patients Safely

And an Israeli startup, Sight Diagnostics — which makes OLO, a CBC machine that uses less blood and gets test results faster — has just announced that an Israeli government hospital is using OLO to test the blood of COVID-19 patients being treated in a separate field hospital.

Read more here.

The post [Sight Diagnostics in Forbes] Complete Blood Count Testers Say Their Products Can Monitor COVID-19 Patients Safely appeared first on OurCrowd.

OurCrowd